Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857684 · ClinicalTrials.gov registry record · Early Phase 1
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
A Early Phase 1 study of Hepatocellular Carcinoma and Resectable Hepatocellular Carcinoma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04857684 is a Early Phase 1 study of Hepatocellular Carcinoma and Resectable Hepatocellular Carcinoma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04857684, a Early Phase 1 study of Hepatocellular Carcinoma and Resectable Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: * Atezolizumab * Bevacizumab * Stereotactic Beam Radiation Therapy (SBRT) * Surgery
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- RADIATION Stereotactic Beam Radiation Therapy (SBRT)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2027-04-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857684
The ClinicalTrials.gov registry entry for NCT04857684 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT04857684 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04857684 about?
NCT04857684 is a clinical study titled "SBRT + Atezolizumab + Bevacizumab in Resectable HCC". This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: * Atezolizumab * Bevacizumab * Stereotactic Beam...
What is the current status of trial NCT04857684?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2021-06-18. Estimated completion is 2027-04-29.
What conditions does trial NCT04857684 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT04857684?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Stereotactic Beam Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT04857684?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04857684 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
COMPLETED · Early Phase 1
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
Explore more on PlainTrial
Hepatocellular Carcinoma
All registered trials for this condition
Resectable Hepatocellular Carcinoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.